GPC1 and esophageal adenocarcinoma: To the best of our knowledge, this study represents the inaugural investigation proposing that GPC-1 demonstrates potential as a therapeutic target in augmenting the chemosensitivity of therapy resistant poorly differentiated esophageal adenocarcinoma.